Dasatinib as First-Line Therapy in Treating Patients With Gastrointestinal Stromal Tumors
Status:
Completed
Trial end date:
2018-05-16
Target enrollment:
Participant gender:
Summary
RATIONALE: Dasatinib may stop the growth of tumor cells by blocking some of the enzymes
needed for cell growth.
PURPOSE: This phase II trial is studying how well dasatinib works as first-line therapy in
treating patients with gastrointestinal stromal tumors.